Automated Expansion of Primary Human T Cells in Scalable and Cell‐Friendly Hydrogel Microtubes for Adoptive Immunotherapy

Adoptive immunotherapy is a highly effective strategy for treating many human cancers, such as melanoma, cervical cancer, lymphoma, and leukemia. Here, a novel cell culture technology is reported for expanding primary human T cells for adoptive immunotherapy. T cells are suspended and cultured in microscale alginate hydrogel tubes (AlgTubes) that are suspended in the cell culture medium in a culture vessel. The hydrogel tubes protect cells from hydrodynamic stresses and confine the cell mass less than 400 µm (in radial diameter) to ensure efficient mass transport, creating a cell-friendly microenvironment for growing T cells. This system is simple, scalable, highly efficient, defined, cost-effective, and compatible with current good manufacturing practices. Under optimized culture conditions, the AlgTubes enable culturing T cells with high cell viability, low DNA damage, high growth rate (≈320-fold expansion over 14 days), high purity (≈98% CD3+), and high yield (≈3.2 × 108 cells mL-1 hydrogel). All offer considerable advantages compared to current T cell culturing approaches. This new culture technology can significantly reduce the culture volume, time, and cost, while increasing the production.

[1]  R. Orentas,et al.  Towards a commercial process for the manufacture of genetically modified T cells for therapy , 2015, Cancer Gene Therapy.

[2]  Vladimir Mironov,et al.  Tissue spheroid fusion‐based in vitro screening assays for analysis of tissue maturation , 2010, Journal of tissue engineering and regenerative medicine.

[3]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[4]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[5]  Stefan Miltenyi,et al.  Integrated Clinical Scale Manufacturing System for Cellular Products Derived by Magnetic Cell Separation, Centrifugation and Cell Culture , 2013 .

[6]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[7]  M. Sabatino,et al.  Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates , 2016, Transfusion.

[8]  P. Itsykson,et al.  Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension , 2010, Nature Biotechnology.

[9]  S. Rosenberg,et al.  Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor , 2012, Journal of Translational Medicine.

[10]  I. Pastan,et al.  Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers , 2010, Clinical Cancer Research.

[11]  M. Dudley,et al.  Bioreactors get personal , 2012, Oncoimmunology.

[12]  G. Kvalheim,et al.  Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. , 2010, Journal of immunological methods.

[13]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[14]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Praveen Shukla,et al.  Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. , 2015, Stem cell research.

[16]  X. Wang,et al.  Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies , 2015, Cancer Gene Therapy.

[17]  R. McKay,et al.  Developmental insights from early mammalian embryos and core signaling pathways that influence human pluripotent cell growth and differentiation. , 2014, Stem cell research.

[18]  Andreas Fouras,et al.  Flow Characterization of a Spinner Flask for Induced Pluripotent Stem Cell Culture Application , 2014, PloS one.

[19]  S. Riddell,et al.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. , 2011, Blood.

[20]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[21]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[22]  K. Peggs,et al.  Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. , 2016, Cytotherapy.

[23]  Todd C McDevitt,et al.  The multiparametric effects of hydrodynamic environments on stem cell culture. , 2011, Tissue engineering. Part B, Reviews.

[24]  S. Rosenberg,et al.  High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  B. Levine,et al.  Adoptive immunotherapy for cancer or viruses. , 2014, Annual review of immunology.

[26]  A. Cerwenka,et al.  Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy , 2015, Cytotherapy.

[27]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[28]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Melissa A. Kinney,et al.  Hydrodynamic modulation of pluripotent stem cells , 2012, Stem Cell Research & Therapy.

[30]  R. McKay,et al.  Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. , 2014, Cell stem cell.

[31]  David V. Schaffer,et al.  A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation , 2013, Proceedings of the National Academy of Sciences.

[32]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[33]  Marianna Sabatino,et al.  Simplified Method of the Growth of Human Tumor Infiltrating Lymphocytes in Gas-permeable Flasks to Numbers Needed for Patient Treatment , 2012, Journal of immunotherapy.

[34]  Yuguo Lei,et al.  Developing Defined and Scalable 3D Culture Systems for Culturing Human Pluripotent Stem Cells at High Densities , 2014, Cellular and molecular bioengineering.

[35]  W. Wilson,et al.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.

[36]  Catarina Brito,et al.  Process engineering of human pluripotent stem cells for clinical application. , 2012, Trends in biotechnology.

[37]  Y. Lei,et al.  Scalable Production of Glioblastoma Tumor-initiating Cells in 3 Dimension Thermoreversible Hydrogels , 2016, Scientific Reports.

[38]  Y. Lei,et al.  An Integrated Miniature Bioprocessing for Personalized Human Induced Pluripotent Stem Cell Expansion and Differentiation into Neural Stem Cells , 2017, Scientific Reports.

[39]  C. Gahmberg,et al.  LFA-1 integrin antibodies inhibit leukocyte α4β1-mediated adhesion by intracellular signaling. , 2016, Blood.

[40]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[41]  D. Porter,et al.  Chimeric antigen receptor T cell therapy: 25years in the making. , 2016, Blood reviews.

[42]  D. Mooney,et al.  Alginate: properties and biomedical applications. , 2012, Progress in polymer science.

[43]  Michel Sadelain,et al.  Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy , 2009, Journal of immunotherapy.

[44]  S. Rosenberg,et al.  Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[46]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[47]  Suzanne S Farid,et al.  Human pluripotent stem cell-derived products: Advances towards robust, scalable and cost-effective manufacturing strategies , 2014, Biotechnology journal.

[48]  G. Schuler,et al.  Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer , 2009, Gene Therapy.

[49]  S. Katz,et al.  Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases , 2015, Clinical Cancer Research.

[50]  Robert Zweigerdt,et al.  Controlling Expansion and Cardiomyogenic Differentiation of Human Pluripotent Stem Cells in Scalable Suspension Culture , 2014, Stem cell reports.

[51]  Wee Keat Chong,et al.  Time-resolved video analysis and management system for monitoring cardiomyocyte differentiation processes and toxicology assays. , 2014, Biotechnology journal.

[52]  B. Levine Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells , 2015, Cancer Gene Therapy.

[53]  David Hsu,et al.  Optimizing the production of suspension cells using the G-Rex “M” series , 2014, Molecular therapy. Methods & clinical development.

[54]  H. Abken,et al.  Cancer gene therapy with T cell receptors and chimeric antigen receptors. , 2015, Current opinion in pharmacology.

[55]  Anthony Walker,et al.  Commercialization of cellular immunotherapies for cancer. , 2016, Biochemical Society transactions.

[56]  S. Jagannath,et al.  BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity , 2012 .